Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 16/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833965 | 0.92 | MGLL (0.49) | MGLLADRB1HTR1ADRD2HTR1D | |
| SCHEMBL19834079 | 0.92 | MGLL (0.57) | MGLLADRB1HTR1ADRD2HTR1D | |
| SCHEMBL19833794 | 0.92 | MGLL (0.67) | MGLL | |
| SCHEMBL19833726 | 0.92 | MGLL (0.58) | MGLLTP53ADRB1HTR1ADRD2 | |
| SCHEMBL19833711 | 0.89 | MGLL (0.57) | MGLLTP53HTR1AHTR1DHTR1B | |
| SCHEMBL19833782 | 0.89 | MGLL (0.55) | MGLL | |
| SCHEMBL19833959 | 0.89 | MGLL (0.55) | MGLLTP53DRD2DRD3 | |
| SCHEMBL19834037 | 0.88 | MGLL (0.51) | MGLLTP53ADRB1HTR1ADRD2 | |
| SCHEMBL19834164 | 0.88 | MGLL (0.54) | MGLLTP53ADRB1HTR1ADRD2 | |
| SCHEMBL19833999 | 0.87 | MGLL (0.53) | MGLLTP53ADRB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | MGLL 129/4885RECQL 1660/4885TP53 1722/4885 |
| US-10106556-B2 | Heterocyclic compound | MAG, ACHE, HTT | MGLL 129/4885RECQL 1660/4885TP53 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.